Isofol Medical AB (publ) (STO:ISOFOL)

Sweden · Delayed Price · Currency is SEK

0.6820

-0.0120 (-1.73%)

Jun 12, 2026, 9:52 AM CET

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Development of the Drug Candidate Arfolitixorin			721.00K	12.80M	22.41M	37.12M			227.00K
Development of the Drug Candidate Arfolitixorin Growth			-94.37%	-42.89%	-39.63%	-			-55.31%
Total			721.00K	12.80M	22.41M	37.12M			227.00K
Total Growth			-94.37%	-42.89%	-39.63%	-			-55.31%

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Asia			721.00K	12.80M	22.41M	26.03M			-
Asia Growth			-94.37%	-42.89%	-13.92%	-			-
North America			-	-	-	11.09M			-
Sweden			-	-	-	-			227.00K
Sweden Growth			-	-	-	-			-55.31%
Total			721.00K	12.80M	22.41M	37.12M			227.00K
Total Growth			-94.37%	-42.89%	-39.63%	-			-55.31%

Source: S&P Global Market Intelligence.